Package Leaflet: Information for the User
Colobreathe 1.662.500 UI powder for inhalation, hard capsules
colistimethate sodium
Read all of this leaflet carefully before you start using this medicine, because it contains important information for you.
Contents of the pack
Colobreathe contains colistimethate sodium, a type of antibiotic called polymyxin.
Colobreathe is used to control persistent lung infections caused by the bacterium Pseudomonas aeruginosain adult and child patients 6 years of age and older with cystic fibrosis. Pseudomonas aeruginosais a very common bacterium that infects almost all patients with cystic fibrosis at some point in their lives. Some people get this infection while they are very young, but for others it happens much later. If this infection is not properly controlled, it will cause lung damage.
How it works
Colobreathe works by destroying the bacterial cell membrane, with a lethal effect on these bacteria.
Do not use Colobreathe:
Warnings and precautions
Talk to your doctor or pharmacist before you start using Colobreathe.
Tell your doctor if you/your child has ever suffered from any of the following conditions:
After each inhalation of Colobreathe, you should rinse your mouth with water. The rinse should not be swallowed. The rinse can reduce the risk of developing oral fungal infections during treatment and can also reduce the unpleasant taste associated with colistimethate sodium.
When you/your child starts using Colobreathe, you/your child may find that you have a cough, difficulty breathing, chest tightness or wheezing (a whistling sound that occurs when breathing). The number of these side effects can be reduced as you continue to use the inhaler or your doctor may prescribe a bronchodilator for you to use before or after taking Colobreathe. If any of these effects become a problem, please contact your doctor who may change your treatment.
If you/your child has any kidney or nerve problems, you should be extremely careful when taking Colobreathe, although your doctor will already be aware of this.
If you/your child needs to take other forms of colistimethate, either by injection or by nebulisation, you should be extremely careful, although your doctor will already be aware of this.
Children
Do not give Colobreathe to children under 6 years of age, as it is not suitable for them.
Other medicines and Colobreathe
Tell your doctor if you/your child is taking, has recently taken or might take any other medicines, and in particular:
Pregnancy and breast-feeding
If you are pregnant or breast-feeding, think you may be pregnant or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.
There is no information on the safety of Colobreathe in pregnant women. Your doctor will advise you on whether the benefits of the medicine outweigh the risks.
Colistimethate sodium may pass into breast milk. Discuss the use of Colobreathe with your doctor.
Driving and using machines
You may experience dizziness, confusion or have problems with your vision while using Colobreathe. Do not drive or operate machinery until the symptoms have disappeared.
Colobreathe contains sodium
This medicine contains less than 1 mmol of sodium (23 mg) per capsule; this is essentially “sodium-free”.
Follow the instructions for administration of the medicine contained in this leaflet or as directed by your doctor. If you are in doubt, ask your doctor if you/your child has doubts.
The first dose should be given under medical supervision.
The recommended dose is
Adults and children 6 years of age and older
The order in which you should take or perform other treatments
If you/your child is taking other treatments for cystic fibrosis, you/your child should take them in the following order:
You/your child should confirm the order of your treatments with your doctor.
Method of administration
Colobreathe is inhaled into the lungs as a powder from the capsule using the manual inhaler called Turbospin. Colobreathe can only be administered using this device.
Do not swallow Colobreathe capsules.
To inhale Colobreathe from the capsule using the Turbospin inhaler, follow the procedure described below. Your doctor, pharmacist or nurse should show you/your child how to inhale the medicine when you/your child start treatment:
Using Colobreathe with the Turbospin inhaler
Preparing the Turbospin
Piercing the capsule and inhaling the medicine
Removing the empty capsule from the Turbospin
Additional information
When you breathe in slowly, you draw air through the body of the Turbospin inhaler into the capsule chamber. The tiny particles of medicine from the capsule are picked up by the airflow and carried through your airways to your lungs.
Occasionally, very small pieces of the capsule casing may enter your mouth or airways.
Cleaning the Turbospin device
Clean the Turbospin inhaler after each dose using the following procedure:
If you/your child uses more Colobreathe than you should, or if you have accidentally swallowed a capsule,contact your doctor immediately for help.
If you/your child misses a dose of Colobreathe
If you/your child forgets to take a dose of Colobreathe, then you/your child should take the missed dose as soon as you/your child remembers. You/your child should not take 2 doses in less than 12 hours. Continue from there as directed.
If you/your child stops treatment with Colobreathe
Do not stop your treatment prematurely unless your doctor tells you to. Your doctor will decide how long your treatment/your child’s treatment should last.
If you/your child has any other questions about the use of this medicine, ask your doctor.
Like all medicines, this medicine can cause side effects, although not everybody gets them.
Allergic reactions
An allergic reaction with Colobreathe is possible (usually serious allergic reactions can cause skin rash, swelling of the face, tongue and throat, difficulty breathing due to narrowing of the airways and loss of consciousness). If you/your child experiences signs of an allergic reaction, you must seek urgent medical attention.
Other possible side effects
You/your child may have an unpleasant taste in your mouth after inhaling Colobreathe.
Very common (may affect more than 1 in 10 people):
Common (may affect up to 1 in 10 people):
Uncommon (may affect up to 1 in 100 people):
The side effects described above have been seen in people of all ages with a similar frequency.
Reporting of side effects
If you experience any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report side effects directly through the national reporting system listed in Appendix V. By reporting side effects, you can help provide more information on the safety of this medicine.
Keep this medicine out of the sight and reach of children.
Do not use this medicine after the expiry date which is stated on the outer packaging and on the blister pack after EXP. The expiry date is the last day of the month shown.
Do not store Colobreathe above 25°C.
Store in the original package to protect from moisture.
If you/your child accidentally peels off the foil and a capsule is exposed, please discard that capsule.
Discard the Turbospin inhaler after completion of a treatment pack.
Medicines should not be disposed of via wastewater or household waste. Ask your pharmacist how to dispose of medicines no longer required. This will help protect the environment.
Composition of Colobreathe
The active ingredient is sodium colistimethate. Each capsule contains 1,662,500 IU (approximately equivalent to 125 mg) of sodium colistimethate.
The other components are:
Capsule shell
Gelatin
Polyethylene glycol
Sodium lauryl sulfate
Purified water
Appearance of the product and container contents
Colobreathe powder for inhalation, hard capsule (powder for inhalation) is supplied in small, hard, transparent gelatin capsules containing a fine white powder.
The Turbospin is a dry powder inhaler driven by the inspiratory flow, manufactured from polypropylene and stainless steel.
The capsules are packaged in blisters, which are supplied in boxes containing:
Only some pack sizes may be marketed.
Marketing authorization holder
Essential Pharma Limited,
Vision Exchange Building,
Territorials Street, Zone 1,
Central Business District,
Birkirkara, CBD 1070,
Malta
Manufacturer
Teva Pharmaceuticals Europe BV
Swensweg 5
2031 GA Haarlem
Netherlands.
Millmount Healthcare Limited
Block 7, City North Business Campus
Stamullen
Co Meath
K32 YD60
Ireland
Merckle GmbH
Ludwig-Merckle-Str-3
89143 Blaubeuren
Germany
Laboratorios Liconsa, S.A.
Miralcampo Avenue, 7, Industrial Estate
Miralcampo
19200 Azuqueca de Henares (Guadalajara)
Spain
Date of last revision of this leaflet: February 2024.
Detailed information on this medicinal product is available on the European Medicines Agency website: http://www.ema.europa.eu. There are also links to other websites on rare diseases and orphan medicines.